Hlavaty et al used the Apoptotic Pharmacogenetic Index (API) to predict response to infliximab therapy by a patient with Crohn's disease. The components of the API are associated with the apoptotic response of immune cells to infliximab therapy. The authors are from University Hospital Gasthuisberg in Leuven, Belgium, and University Hospital Bratislava in Slovakia.
